Skip to content

Short Treatment Effect Evaluation of Transcranial Pulsed Electrical Stimulation for Adolescents with Attention-Deficit/Hyperactivity Disorder

Short Treatment Effect Evaluation of Transcranial Pulsed Electrical Stimulation for Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Sham-Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102586
Enrollment
Unknown
Registered
2025-05-16
Start date
2025-07-20
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

Test group:Transcranial pulsed current stimulation
Control group:Sham Transcranial pulsed current stimulation

Sponsors

Chengdu Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1: Age 7~18 years; 2: Meet the diagnostic criteria for attention deficit hyperactivity disorder (ADHD) in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); 3: Participants and legal guardians sign written informed consent to confirm their voluntary participation in the study; 4: No history of diagnosis of other neurodevelopmental disorders, serious physical diseases or comorbidities; 5: Normal visual and auditory function (corrected visual acuity >=1.0, pure tone audiometry threshold =4 weeks; 8: There was no known diagnosis of specific diseases other than ADHD.

Exclusion criteria

Exclusion criteria: 1: Failure to meet the above inclusion criteria; 2: Age >18 years; 3: Comorbid neurodevelopmental disorders (e.g., autism spectrum disorder, intellectual disability); 4: History of chronic neurological diseases (e.g., epilepsy) or severe systemic diseases (e.g., cancer); 5: Subjects with severe mental disorders (e.g., schizophrenia) or family history of psychosis; 6: Skull defects at stimulation sites or severe scalp infections; 7: History of craniotomy, any photosensitivity or metal implants in head/body (e.g., cochlear implants, pacemakers or defibrillators), or severe neurological disorders (e.g., brain tumors and intracranial infections); 8: Current use of benzodiazepines, neuroleptics and antipsychotics (e.g., risperidone and haloperidol); 9: Participation in other clinical trials within the past 1 month.

Design outcomes

Primary

MeasureTime frame
integrated value of oxygenated hemoglobin concentration;

Secondary

MeasureTime frame
Subjective level of attention concentration;ADHD-RS-IV questionnaire;

Countries

China

Contacts

Public ContactYang Ying

Chengdu Second People's Hospital

lotus654321@126.com+86 184 8365 2838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026